After Bristol Myers (BMY) announced this morning that the ADEPT-2 study of Cobenfy in in Alzheimer’s disease psychosis will continue enrolling additional patients after a review identified irregularities due to trial conduct at some sites, Stifel analyst Paul Matteis contends that the study continuation has “grey implications, but at face is a win” for MapLight Therapeutics (MPLT) and overall this is a positive, though there are some lingering questions. For MapLight, the firm thinks there’s a chance that their muscarinic drug has a wider therapeutic index in elderly subjects and the firm sees “an upside risk/reward” as the current valuation “arguably prices in very little ADP credit.” Stifel has a Buy rating and $28 price target on MapLight shares, which are up $3.61, or 28%, to $16.50 in morning trading.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT:
- MapLight Therapeutics initiated with an Outperform at Leerink
- Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials
- Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
- MapLight Therapeutics initiated with a Buy at Stifel
- MapLight Therapeutics initiated with a Buy at Jefferies